Long-term Metabolic Effects of Non-Nutritive Sweeteners.

Glucose Metabolism Insulin Sensitivity Microbiome Non-Nutritive Sweeteners Obesity Reb M

Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
06 Jul 2024
Historique:
received: 24 05 2024
revised: 02 07 2024
accepted: 03 07 2024
medline: 9 7 2024
pubmed: 9 7 2024
entrez: 8 7 2024
Statut: aheadofprint

Résumé

Excessive consumption of added sugars has been linked to the rise in obesity and associated metabolic abnormalities. Non-nutritive sweeteners (NNSs) offer a potential solution to reduce sugar intake, yet their metabolic safety remains debated. This study aimed to systematically assess the long-term metabolic effects of commonly used NNSs under both normal and obesogenic conditions. To ensure consistent sweetness level and controlling for the acceptable daily intake (ADI), eight weeks old C57BL/6 male mice were administered with acesulfame K (ace K, 535.25 mg/L), aspartame (411.75 mg/L), sucralose (179.5 mg/L), saccharin (80 mg/L), or steviol glycoside (Reb M, 536.25 mg/L) in the drinking water, on the background of either regular or high-fat diets (in high fat diet 60% of calories from fat). Water or fructose-sweetened water (82.3.gr/L), were used as controls. Anthropometric and metabolic parameters, as well as microbiome composition, were analyzed following 20-weeks of exposure. Under a regular chow diet, chronic NNS consumption did not significantly affect body weight, fat mass, or glucose metabolism as compared to water consumption, with aspartame demonstrating decreased glucose tolerance. In diet-induced obesity, NNS exposure did not increase body weight or alter food intake. Exposure to sucralose and Reb M led to improved insulin sensitivity and decreased weight gain. Reb M specifically was associated with increased prevalence of colonic Lachnospiracea bacteria. Long-term consumption of commonly used NNSs does not induce adverse metabolic effects,with Reb M demonstrating a mild improvement in metabolic abnormalities. These findings provide valuable insights into the metabolic impact of different NNSs, aiding in the development of strategies to combat obesity and related metabolic disorders.

Identifiants

pubmed: 38977130
pii: S2212-8778(24)00116-9
doi: 10.1016/j.molmet.2024.101985
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101985

Informations de copyright

Copyright © 2024. Published by Elsevier GmbH.

Auteurs

Moran Rathaus (M)

The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel.

Loziana Azem (L)

The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Rinat Livne (R)

The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel.

Sophie Ron (S)

The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Idit Ron (I)

The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel.

Rotem Hadar (R)

Sheba Medical Center, Tel-Hashomer, affiliated with the Tel-Aviv University, Israel.

Gilat Efroni (G)

Sheba Medical Center, Tel-Hashomer, affiliated with the Tel-Aviv University, Israel.

Amnon Amir (A)

Sheba Medical Center, Tel-Hashomer, affiliated with the Tel-Aviv University, Israel.

Tzipi Braun (T)

Sheba Medical Center, Tel-Hashomer, affiliated with the Tel-Aviv University, Israel.

Yael Haberman (Y)

Sheba Medical Center, Tel-Hashomer, affiliated with the Tel-Aviv University, Israel; Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio.

Amir Tirosh (A)

The Dalia and David Arabov Endocrinology and Diabetes Research Center, Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: Amir.Tirosh@sheba.health.gov.il.

Classifications MeSH